1. Fettiplace, A, Stainsby, C, Winston, A, et al. Psychiatric symptoms in patients receiving dolutegravir. J Acquir Immune Defic Syndr 2017; 74: 423–431.
Google Scholar | Crossref | Medline | ISI2. Lowther, K, Selman, L, Harding, R, et al. Experience of persistent psychological symptoms and perceived stigma among people with HIV on antiretroviral therapy (ART): a systematic review. Int J Nurs Stud 2014; 51: 1171–1189.
Google Scholar | Crossref | Medline3. Rabkin, JG . HIV and depression: 2008 review and update. Curr HIV/AIDS Rep 2008; 5: 163–171.
Google Scholar | Crossref | Medline4. Reid, S, Dwyer, J. Insomnia in HIV infection: a systematic review of prevalence, correlates, and management. Psychosom Med 2005; 67: 260–269.
Google Scholar | Crossref | Medline5. Hoffmann, C, Llibre, JM. Neuropsychiatric adverse events with dolutegravir and other integrase strand transfer inhibitors. AIDS Rev 2019; 21: 4–10.
Google Scholar | Crossref | Medline6. Paolillo, EW, Gongvatana, A, Umlauf, A, et al. At-risk alcohol use is associated with antiretroviral treatment nonadherence among adults living with HIV/AIDS. Alcohol Clin Exp Res 2017; 41: 1518–1525.
Google Scholar | Crossref | Medline7. Whiteford, HA, Ferrari, AJ, Degenhardt, L, et al. The global burden of mental, neurological and substance use disorders: an analysis from the Global Burden of Disease Study 2010. PLoS One 2015; 10: e0116820.
Google Scholar | Crossref | Medline | ISI8. Gibson, TB, Lee, TA, Vogeli, CS, et al. A four-system comparison of patients with chronic illness: the Military Health System, Veterans Health Administration, Medicaid, and commercial plans. Mil Med 2009; 174: 936–943.
Google Scholar | Crossref | Medline | ISI9. Plana-Ripoll, O, Pedersen, CB, Holtz, Y, et al. Exploring comorbidity within mental disorders among a Danish national population. JAMA Psychiatry 2019; 76: 259–270.
Google Scholar | Crossref | Medline10. Panel on Antiretroviral Guidelines for Adults and Adolescents . Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Available at: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf (Accessed 9 June 2021).
Google Scholar11. Mills, AM, Antinori, A, Clotet, B, et al. Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks. HIV Med 2013; 14: 391–400.
Google Scholar | Crossref | Medline12. Peñafiel, J, de Lazzari, E, Padilla, M, et al. Tolerability of integrase inhibitors in a real-life setting. J Antimicrob Chemother 2017; 72: 1752–1759.
Google Scholar | Crossref | Medline13. Hoffmann, C, Welz, T, Sabranski, M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med 2017; 18: 56–63.
Google Scholar | Crossref | Medline14. Hoffmann, C, Schewe, K, Fenske, S, et al. Short-term neuropsychiatric tolerability of bictegravir combined with FTC/TAF in clinical practice. Poster Presented at: 17th European AIDS Conference; ; Basel, Switzerland.
Google Scholar15. Daar, ES, Tierney, C, Fischl, MA, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011; 154: 445–456.
Google Scholar | Crossref | Medline | ISI16. Dunn, K, Simonson, RB, Luo, D, et al. Use of D/C/F/TAF with neurologic/psychiatric comorbidities: AMBER subgroup analysis. Poster Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); ; Boston, Massachusetts.
Google Scholar17. Dubé, B, Benton, T, Cruess, DG, et al. Neuropsychiatric manifestations of HIV infection and AIDS. J Psychiatry Neurosci 2005; 30: 237–246.
Google Scholar | Medline | ISI18. Scott Sutton, S, Magagnoli, J, Hardin, JW. Impact of pill burden on adherence, risk of hospitalization, and viral suppression in patients with HIV infection and AIDS receiving antiretroviral therapy. Pharmacotherapy 2016; 36: 385–401.
Google Scholar | Crossref | Medline19. Clay, PG, Yuet, WC, Moecklinghoff, CH, et al. A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV. AIDS Res Ther 2018; 15: 17.
Google Scholar | Crossref | Medline20. Centers for Disease Control and Prevention . Behavioral and Clinical Characteristics of Persons with Diagnosed HIV Infection—Medical Monitoring Project, United States, 2017 Cycle (June 2017–May 2018). HIV Surveillance Special Report 23, 2019. Available at: https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-special-report-number-23.pdf (Accessed 29 March 2021).
Google Scholar